Literature DB >> 21883856

Incidence and outcomes of ductal carcinoma of the prostate in the USA: analysis of data from the Surveillance, Epidemiology, and End Results program.

Joshua J Meeks1, Lee C Zhao, John Cashy, Shilajit Kundu.   

Abstract

OBJECTIVE: To use the national Surveillance, Epidemiology, and End Results (SEER) cancer registry to describe the natural history, national incidence and treatment patterns for ductal prostate cancer (PCa) over the last 20 years, as the available literature on ductal PCa is limited to small case series because of few patient numbers. PATIENTS AND METHODS: From the SEER registry, 693 men with ductal PCa were identified from 1970. The demographics, clinical features and cause of death data were collected from men with ductal and acinar histological types.
RESULTS: The incidence of ductal PCa has increased over each decade, but the overall percentage of ductal relative to acinar PCa has remained stable. Men with ductal PCa were more likely to present with advanced disease (30% T3 with ductal PCa, compared with 7% with acinar PCa). Men with ductal PCa underwent similar rates of radical surgery, lower rates of radiotherapy but a higher frequency of outlet (transurethral resection) procedures. Men with ductal PCa had a significantly greater rate of death from PCa (12% vs 4%) than men with acinar PCa. Comparing PCa-specific mortality, men with ductal PCa had similar rates of death to men with Gleason 4 + 4 grade acinar PCa.
CONCLUSIONS: Despite a stable incidence, ductal PCa remains an aggressive PCa usually presenting with advanced clinical stage and resulting in a high rate of PCa-specific mortality similar to Gleason 4 + 4 acinar PCa. Patients would probably benefit from combined modalities including radical surgery, radiotherapy and palliative outlet procedures.
© 2011 BJU INTERNATIONAL. NO CLAIM TO US GOVERNMENT WORKS.

Entities:  

Mesh:

Year:  2011        PMID: 21883856     DOI: 10.1111/j.1464-410X.2011.10520.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  26 in total

1.  Prostatic ductal adenocarcinoma: an aggressive tumour variant unrecognized on T2 weighted magnetic resonance imaging (MRI).

Authors:  Nicola Schieda; Niamh Coffey; Previn Gulavita; Omran Al-Dandan; Wael Shabana; Trevor A Flood
Journal:  Eur Radiol       Date:  2014-04-01       Impact factor: 5.315

2.  PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Authors:  Carlos L Morais; Mehsati Herawi; Antoun Toubaji; Roula Albadine; Jessica Hicks; George J Netto; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan
Journal:  Prostate       Date:  2015-07-14       Impact factor: 4.104

3.  Large cystic ductal carcinoma of the prostate: imaging findings and minimally invasive surgical treatment.

Authors:  Fabio Cesar Miranda Torricelli; Marcos Tucherman; Rodrigo Melogno; Rafael Ferreira Coelho
Journal:  BMJ Case Rep       Date:  2014-11-28

4.  Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort.

Authors:  Amar Bhindi; Bimal Bhindi; Girish S Kulkarni; Robert J Hamilton; Ants Toi; Theodorus H van der Kwast; Andrew Evans; Alexandre R Zlotta; Antonio Finelli; Neil E Fleshner
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

5.  Advanced prostatic ductal carcinoma in a patient with a long survival time following a total pelvis exenteration: A case report.

Authors:  Changwei Ji; Ming Zhou; Weidong Gan; Jinyu Zheng; Xiang Yan; Hongqian Guo
Journal:  Oncol Lett       Date:  2016-01-08       Impact factor: 2.967

6.  Magnetic resonance imaging findings of pure prostatic ductal adenocarcinomas: a case series.

Authors:  Hiromi Edo; Yasuyo Urase; Yoshiko Ueno; Ayumu Kido; Tsutomu Tamada; Yudai Asano; Kentaro Ida; Hisataka Ito; Takashi Koyama; Kosuke Miyai; Hitoshi Tsuda; Hiroshi Shinmoto
Journal:  Abdom Radiol (NY)       Date:  2022-02-28

7.  Ductal adenocarcinoma of the prostate: a Hong Kong case series.

Authors:  Raymond Wai Man Kan; Chi Fai Kan; Joseph Hon Ming Wong; Kenneth Kam Fung Fu; Chi Fai Ng; Steve Wai Hee Chan
Journal:  Int Urol Nephrol       Date:  2014-07-31       Impact factor: 2.370

8.  Immunohistochemical profile of ductal adenocarcinoma of the prostate.

Authors:  Amanda H Seipel; Hemamali Samaratunga; Brett Delahunt; Fredrik Wiklund; Peter Wiklund; Johan Lindberg; Henrik Grönberg; Lars Egevad
Journal:  Virchows Arch       Date:  2014-07-25       Impact factor: 4.064

9.  Prostatic ductal adenocarcinoma: An aggressive variant that is underdiagnosed and undersampled on transrectal ultrasound (TRUS)-guided needle biopsy.

Authors:  Previn Gulavita; Shaheed W Hakim; Nicola Schieda; Rodney H Breau; Chris Morash; Daniel T Keefe; Susan J Robertson; Kien T Mai; Eric C Belanger; Trevor A Flood
Journal:  Can Urol Assoc J       Date:  2015 Sep-Oct       Impact factor: 1.862

Review 10.  Optimizing the diagnosis and management of ductal prostate cancer.

Authors:  Weranja Ranasinghe; Daniel D Shapiro; Miao Zhang; Tharakeswara Bathala; Nora Navone; Timothy C Thompson; Bradley Broom; Ana Aparicio; Shi-Ming Tu; Chad Tang; John W Davis; Louis Pisters; Brian F Chapin
Journal:  Nat Rev Urol       Date:  2021-04-06       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.